@article{e27804522d104e4a8cc9a77873340055,
title = "Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis(Figure presented.)",
abstract = "Restricted mean survival time estimates may be used to benchmark survival outcomes and inform future trial design.Programmed death-1 and programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer yield comparable survival outcomes.",
keywords = "Bladder cancer, Immune checkpoint blockade, Meta-analysis, Programmed death ligand-1 blockade, Programmed death-1 blockade, Urothelial cancer",
author = "Niglio, {Scot A.} and Rachel Jia and Jiayi Ji and Samuel Ruder and Patel, {Vaibhav G.} and Alberto Martini and Sfakianos, {John P.} and Marqueen, {Kathryn E.} and Nikhil Waingankar and Reza Mehrazin and Peter Wiklund and Oh, {William K.} and Madhu Mazumdar and Ferket, {Bart S.} and Galsky, {Matthew D.}",
note = "Funding Information: Financial disclosures: Matthew D. Galsky certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Scot Niglio's domestic partner is employed by STEMCELL Technologies. William Oh has disclosures from AstraZeneca, Bayer, CheckPoint Sciences, Janssen, Sanofi, Sema4, and Tyme Technologies. Matthew D. Galsky has served on an advisory board for Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, and Inovio Pharmaceuticals; has received research funding from Janssen, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, and Genentech/Roche; and is a cofounder of RAPPTA Therapeutics. Rachel Jia, Jiayi Ji, Samuel Ruder, Vaibhav Patel, Alberto Martini, John P. Sfakianos, Kathryn E. Marqueen, Nikhil Waingankar, Reza Mehrazin, Peter Wiklund, Madhu Mazumdar, and Bart Ferket have nothing to disclose. Publisher Copyright: {\textcopyright} 2019 European Association of Urology",
year = "2019",
month = dec,
doi = "10.1016/j.eururo.2019.05.037",
language = "English",
volume = "76",
pages = "782--789",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",
}